2024-12-25 - Analysis Report
## Teladoc Health Inc. (TDOC) Stock Review

**1. Performance Comparison and Divergence:**

Teladoc Health Inc. (TDOC) is a telehealth company providing virtual healthcare services.  As of the last data point, TDOC's cumulative return is -67.81%, significantly underperforming the S&P 500 (VOO) with a cumulative return of 120.64%. The difference in cumulative returns is a substantial -188.5%.  The provided relative divergence metric indicates TDOC is at its lowest historical point relative to the S&P 500 within the observed period.  The extremely negative CAGR figures in the provided table (2019-2024) further highlight the significant underperformance.

**2. Recent Price Movement:**

* **Closing Price:** $9.26
* **5-day Moving Average:** $9.25
* **20-day Moving Average:** $10.48
* **60-day Moving Average:** $9.68

The price is slightly below the 5-day moving average, suggesting recent sideways price action.  It's below both the 20-day and 60-day moving averages, indicating a downtrend.

**3. Technical Indicators and Expected Return:**

* **RSI (29.82):** Suggests the stock is in oversold territory.
* **PPO (-2.33):**  Indicates bearish momentum.
* **Relative Divergence Change (-0.2):** Shows a recent short-term decline in relative performance against the S&P 500.
* **Expected Return (0.0%):** The provided expected return is zero, implying no significant outperformance of the S&P 500 is anticipated over the long term (2+ years).  Given the current negative trend and significant underperformance, this prediction warrants further investigation and independent validation.  The current price of $9.26 doesn't signal a dramatic event (like a sudden spike or crash) based on the provided moving averages.

**4. Recent Earnings Analysis:**

The recent earnings show a consistent trend of negative EPS and relatively stable revenue.  While revenue remains relatively consistent around $0.64B - $0.66B, EPS has shown significant volatility and consistently negative results.  There is no information provided to compare these numbers to analyst expectations, therefore, beats or misses cannot be determined.  The significant negative EPS in Q2 2024 (-$4.92) is a notable outlier.

**5. Financial Information Analysis:**

* **Revenue:** Revenue remains relatively stable but shows a slight downward trend over the last few quarters.
* **Profit Margin:** Profit margins are consistently high (70-72%), despite negative EPS.  This may indicate accounting practices that differ from GAAP or other factors influencing this discrepancy, requiring further investigation.
* **Equity:** Equity has shown significant fluctuations, raising concerns about financial stability.
* **ROE:** ROE is consistently negative, indicating the company is not generating returns on shareholder equity.  This is a significant red flag.

The inconsistency between high profit margins and negative EPS and ROE requires further investigation into the company's accounting practices and financial health.

**6. News and Recent Issues:**

This section requires information on recent news releases (within the last two days) concerning Teladoc Health's earnings, market outlook, and analyst opinions. This data was not included in your provided information.


**7. Overall Analysis:**

TDOC is significantly underperforming the S&P 500, showing a long-term downtrend with consistently negative EPS and fluctuating equity despite relatively stable revenue and high profit margins.  The high profit margins paired with negative ROE and EPS requires further examination.  Technical indicators suggest oversold conditions, but the overall trend is bearish. The provided expected return of 0% reflects the current underperformance and does not offer a positive outlook.  Additional information on recent news, analyst opinions, and a detailed understanding of the company's financial reporting practices is needed for a more comprehensive analysis.  The current situation presents a high-risk investment.

**8. Disclaimer:** This analysis is based solely on the provided data and does not constitute financial advice.  Independent research and consultation with a financial advisor are strongly recommended before making any investment decisions.
